PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

pharmaphorum

OCTOBER 21, 2021

Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. Biogen stumped up $1.525 billion upfront for rights to the drug and another Sage candidate for neurological diseases last year, when the expectation was that Aduhelm was unlikely to get FDA approval.

Insurance 118

Insurance FDA 118

pharmaphorum

APRIL 5, 2022

Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised. mUM is the most common form of cancer affecting the eye in adults, but is still rare, diagnosed in a around 1,700 patients each year in the US, with a few hundred already with metastatic disease that has spread to other tissues.

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

JUNE 12, 2022

bluebird bio started last week on tenterhooks, as FDA advisors cast their eyes over data for two gene therapy candidates that are key to its future as a commercially viable concern. Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8

FDA 59

FDA 59

pharmaphorum

AUGUST 18, 2022

.” The gene therapy specialist’s chief executive Andrew Obenshain said the approval “marks a watershed moment for the field of gene therapy” and is “ushering in a new era in which gene therapy has the potential to transform existing treatment paradigms for diseases that currently carry a lifelong burden of care.”

FDA 52

FDA Insurance 52

pharmaphorum

JANUARY 31, 2023

Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of. Finally, the belief that pharmaceutical companies prioritise their bottom lines over the health and well-being of patients is probably the largest contributing factor to lack of trust in the industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52

The Checkup by Singlecare

JANUARY 25, 2023

Nearly a third of people are not concerned about sun-related skin problems Skin cancer is just one reason to keep an eye on sun exposure, but it’s not the only thing to think about. We asked survey respondents about which risk factors outlined by the Centers for Disease Control and Prevention (CDC) they are aware of.

Documentation 52

Documentation Insurance FDA 52

pharmaphorum

AUGUST 26, 2022

BioMarin will no doubt have an eye on the earlier experience of bluebird bio, which secured EU approval for rare disease gene therapy Zynteglo (betibeglogene autotemcel) in 2019 for beta thalassaemia with a price tag of around €1.6 million spread over five years.

FDA 111

FDA 111

The Checkup by Singlecare

JANUARY 19, 2023

Untreated high blood sugar, especially over time, may result in long-term health complications such as problems with the heart, nerves, kidneys, eyes, and feet. There may also be skin tags in these areas. Diabetes People with diabetes have a fasting blood sugar of 126 mg/dl or more. Diabetes is considered a progressive disease.

Immunization 105

Immunization Hospitals Communication 105

The Physician Pharmacist

SEPTEMBER 14, 2023

We're here to unpack some of these details and open your eyes to the possibility of a career in both pharmacy and medicine. It's very nitpicky, it's very detailed and it's very disease or it's very does disease oriented, I'll say for lack of a better term.

Medical Schools 52

Medical Schools Hospitals Communication Patient Care 52